Nedocromil (EENT)
Class: Antiallergic Agents
- Mast-cell Stabilizers
Chemical Name: 9-Ethyl-6,9-dihydro-4,6-dioxo-10-propyl-4H-pyrano[3,2-g]quinoline-2,8-dicarboxylic acid
Molecular Formula: C19H17NO7
CAS Number: 69409-73-6
Brands: Alocril
Introduction
Mast-cell stabilizer.
Uses for Nedocromil (EENT)
Allergic Conjunctivitis
Symptomatic treatment of ocular itching associated with allergic conjunctivitis.
Nedocromil (EENT) Dosage and Administration
Administration
Ophthalmic Administration
Apply topically to the eye as an ophthalmic solution. Administer at regular intervals.
If more than 1 topical ophthalmic drug is used, administer the drugs at least 10–15 minutes apart.
Avoid contamination of the solution container.
Continue therapy throughout period of exposure (i.e., until pollen season is over or until exposure to offending allergen is terminated), even in absence of symptoms.
Dosage
Available as nedocromil sodium; dosage expressed in terms of the salt.
Pediatric Patients
Allergic Conjunctivitis
Ophthalmic
Children ≥3 years of age: 1 or 2 drops of a 2% solution in each eye twice daily.
Adults
Allergic Conjunctivitis
Ophthalmic
1 or 2 drops of a 2% solution in each eye twice daily.
Cautions for Nedocromil (EENT)
Contraindications
Known hypersensitivity to nedocromil or any ingredient in the formulation.
Warnings/Precautions
General Precautions
Administration
For topical ophthalmic use only.
Specific Populations
Pregnancy
Category B.
Lactation
Distributed into milk in rats following IV administration; not known whether distributed into human milk. Use with caution.
Pediatric Use
Safety and efficacy not established in children <3 years of age.
Geriatric Use
No substantial differences in safety and efficacy relative to younger adults.
Common Adverse Effects
Headache, ocular discomfort (i.e., burning, irritation, stinging ), unpleasant taste, nasal congestion.
Interactions for Nedocromil (EENT)
No formal drug interaction studies to date.
Nedocromil (EENT) Pharmacokinetics
Absorption
Bioavailability
Minimally absorbed (<4%) following topical application to the eye.